Manon de Graaf

MD | PhD candidate at Netherlands Cancer Institute

[Molecular Oncology @MolOncology]

🏆Congratulations to @Manon_deGraaf @NKI_nl for winning a Molecular Oncology prize at the 2024 @CancerCoreEU Summer School, with her poster "In-depth spatial characterisation of the immune landscape in patients with early stage TNBC treated with immune checkpoint blockade"👏

[MarleenKokLab @lab_kok]

Excited to present 🎤 first data #SABCS24 from TONIC2. Follow-up from https://t.co/07YbYYMKQ7. Are immune induction with dox or cisplatin indeed benefiting pts? @VeerleGeurts at P1-7-30 and new data on acquired resist🔬 to aPD1 at PS17-09 @NKI_nl @OncoAlert @NatureMedicine

[Cancer Core Europe (CCE) @CancerCoreEU]

Wrapped up #CCESummSchool24 with fantastic talks on Tumor Microenvironment, Advanced Therapies & Sexual Dimorphism

Congrats to @HandlVerena @MedUniGraz, @MarikaReinius @CRUKCamCentre, @Manon_deGraaf @NKI_nl for Best Posters & @Simon_Linderson @NCT_HD for Best Participant Talk 👏

[MarleenKokLab @lab_kok]

Thanks @ACIR_org for putting our work on neoadjuvant immunotherapy for TNBC in the spotlight @riannerolfes @Manon_deGraaf @LambrechtsDlab @NatureMedicine

[Myriam Chalabi @MyriamChalabi]

Young talent Manon de Graaf from @NKI_nl @lab_kok presenting data on patients with stage 1 TNBC. Good registries 🙏 to @IKNL allow for analysis of populations excluded from most trials! #ESMO24 #ESMOAmbassadors #YOC

[Paolo Tarantino @PTarantinoMD]

Brilliant registry study by @Manon_deGraaf, looking at outcomes for pts with stage I TNBC receiving NACT. pCR rate 57%, associated w/ improved OS (5% 4y delta). Unclear benefit of adjuvant capecitabine. Potential role for ADCs to improve outcomes in this highly incident disease?

[Paolo Tarantino @PTarantinoMD]

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm

[Manon de Graaf @Manon_deGraaf]

Thanks @OncoAlert for highlighting our research on neoadjuvant chemo for stage I TNBC @lab_kok . See you in Barcelona! #ESMO2024

[OncoAlert @OncoAlert]

Dear Colleagues,
The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ESMO24

This List Curated by: #OncoAlertAF Leads
@ElisaAgostinett 🇮🇹
@to_be_elizabeth 🇮🇹
@Lucarecco 🇮🇹
@weoncologists 🇺🇸

With our distinguished OncoAlert Faculty:
@stolaney1 🇺🇸@E_de_Azambuja 🇧🇪@hoperugo 🇺🇸@matteolambe 🇮🇹@Icro_Meattini 🇮🇹& @kevinpunie 🇧🇪

LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study. Peter Schmid (London, United Kingdom🇬🇧)- Discussant @lab_kok
Date: Sun, 15.09.2024
Time 16:30 - 16:42

LBA13 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (Pts) With HR+/HER2− Early Breast Cancer (EBC): 4-Year Outcomes from the NATALEE Trial. Peter A. Fasching (Erlangen, Germany🇩🇪)
Date: Mon, 16.09.2024
Time 11:15 - 11:25

LBA18 Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results. @nlinmd (Boston, United States of America🇺🇸 @DanaFarber ) Discussant Cristina Laura of @VHIO
Date: Fri, 13.09.2024
Time: 16:00 - 16:10

LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): the CAPItello-290 Phase 3 trial @hmcarthur (Dallas, United States of America🇺🇸 @UTSWMedCenter )
Date: Fri, 13.09.2024
Time: 16:45 - 16:55

LBA21 Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). Giuseppe Viale (Milan, Italy🇮🇹 @IEOufficiale )Discussant @c_sotiriou of @JulesBordet
Date: Sun, 15.09.2024
Time: 08:40 - 8:50

LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria. Juan De la Haba Rodriguez (Cordoba, Spain🇪🇸)
Date: Mon, 16.09.2024
Time: 09:00 - 9:20

236MO Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study @Manon_deGraaf (Amsterdam, Netherlands🇳🇱) Discussant @DrLisaCarey
Date: Sat, 14.09.2024
Time: 10:45 - 10:50

LBA10 - Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body
radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-
adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC) @AlexDeCaluwe (Brussels, Belgium🇧🇪)
Date: Mon, 16.09.2024
Time : 10:55 - 11:05

LBA17 - Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial Oleg Gluz (Mönchengladbach, Germany🇩🇪)
Date: Sat, 14.09.2024
Time : 10:15 - 11:55

232O - Effects of a high-intensity exercise intervention on recurrence and survival: The OptiTrain breast cancer trial @HHeleneru (Stockholm, Sweden🇸🇪)
Date: Mon, 16.09.2024
Time: 10:25 - 10:35

Ping #BreastCancer Faculty
@DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @IBCResearch @raalbany @JaniceTNBCmets

#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @orellanauro

[The Netherlands Cancer Institute @NKI_nl]

Patients with triple negative breast cancer and high immune cell (TILs) counts in their tumors have better survival rates even without chemotherapy. Study by @lab_kok highlights that these TILs are key in predicting recovery ➡️ https://t.co/3UMVVChNLt
#BreastCancer #Research